Annovis Bio's Alzheimer's Candidate To Proceed Into Final Cohort Of Mid-Stage Study, Data Expected In 2022

by Vandana Singh, Benzinga Editor

July 20, 2021 12:32 PM | 1 min read |

Data Safety Monitoring Board (DSMB) has reviewed safety and tolerability data for Cohort 2 of Annovis Bio Inc's ANVS Phase 2 Alzheimer's disease trial evaluating ANVS401.
The DSMB has approved the study to proceed with Cohort 3, the final cohort of the study.
Funding for this research was provided by a grant from the National Institutes on Aging. The study is run by the Alzheimer's Disease Cooperative Study (ADCS) at the University of California San Diego School of Medicine.
The safety evaluation of Cohort 2, conducted by the DSMB, reviewed data from an additional eight patients treated with ANVS401 at a dosage of 120 mg per day (2x60 mg) or placebo.
The final data readout from the study is expected next year.
Price Action: ANVS shares are down 1.58% at $98.92 during the market session on the last check Tuesday.

Posted In:

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.